Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.
Humans
Anticoagulants
/ adverse effects
Atrial Fibrillation
/ complications
Coronary Artery Disease
/ complications
Hemorrhage
/ chemically induced
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ adverse effects
Risk Factors
Rivaroxaban
/ adverse effects
Thrombocytopenia
/ epidemiology
Treatment Outcome
atrial fibrillation
chronic coronary syndrome
thrombocytopenia
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
17 10 2023
17 10 2023
Historique:
medline:
1
11
2023
pubmed:
10
10
2023
entrez:
10
10
2023
Statut:
ppublish
Résumé
Background Thrombocytopenia poses a risk of bleeding in patients with chronic coronary syndrome after coronary intervention. However, whether thrombocytopenia also increases the bleeding risk in patients with atrial fibrillation and chronic coronary syndrome remains unclear. Methods and Results This study evaluated the AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial. Thrombocytopenia was defined as platelet count <100 000/mm
Identifiants
pubmed: 37815031
doi: 10.1161/JAHA.123.031096
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Banques de données
ClinicalTrials.gov
['NCT02642419']
UMIN-CTR
['UMIN000016612']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM